TELA Bio, Inc. TELA
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2019-11-08
TELA Bio, Inc. statistics & valuation
Market cap$31.6M
P / S0.4×
P / B5.0×
Net margin-48.4%
FCF margin-35.7%
Net debt$4.8M
Enterprise value USD$36.4M
Earnings yield EBIT/EV-92.7%
Return on capital-53.2%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 67.7% | 67.1% | 68.6% | 65.3% | 63.9% | 61.7% | 60.0% | 35.6% |
| Operating margin | -42.0% | -49.2% | -75.4% | -94.2% | -100.0% | -138.8% | -124.1% | -214.9% |
| Net margin | -48.4% | -54.6% | -79.8% | -106.9% | -112.9% | -158.1% | -145.2% | -254.9% |
| FCF margin | -35.7% | -61.4% | -70.9% | -100.5% | -105.4% | -135.2% | -166.5% | -241.6% |
| Return on assets | -47.7% | -43.7% | -59.8% | -65.3% | -53.2% | -33.3% | -33.0% | -77.5% |
| Return on equity | -615.1% | -133.0% | -247.1% | -309.7% | -165.6% | -58.7% | -72.4% | 15.3% |
| Debt / equity | 8.82× | 1.45× | 2.15× | 2.79× | 1.57× | 0.63× | 0.98× | — |
| Current ratio | 4.20 | 5.01 | 4.23 | 5.03 | 5.58 | 12.60 | 9.58 | 2.43 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.